drugset / Trial / NCT00536510

Effect of MK0524A on Cholesterol Levels (0524A-048)

NCT00536510

Phase 3 Completed 646 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to assess the effects of MK0524A in reducing cholesterol levels in an Asian population.

Timeline

Start
2007-04
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule 2 g
Subject laropiprant Small molecule 40 mg

Indications